The increasing number of diabetes cases worldwide has created a demand for self-injection systems, which are easily met by needle free injection systems.
Needle-Free Injection Market Overview:
The Needle Free Injection Market is projected to reach USD 142.70 Million by 2030 at 17.50% CAGR during the forecast period 2022-2030. Humans have traditionally received drugs via needles and injections. However, needle-free injection technology (NFIT), a revolutionary concept that encompasses a wide range of medication delivery devices, has just hit the market. The rising number of diabetes patients throughout the world has generated a need for self-injection systems, which can easily be satisfied by needle-free injection systems; as a result, the market's growth is being propelled by the rising demand for self-medication.
In addition, the frequency of chronic illnesses and the use of injectable drugs for therapy are driving up the demand for needle-free injection methods. Injectable drug delivery methods provide several benefits over oral drug delivery systems, including a faster start of the action and maximal bioavailability, making them suitable for use in emergency settings.Segment Overview
By product type, the needle free injection market has been segmented into prefilled and fillable needle free injectors. By technology, the needle free injection market is segmented into laser-powered, spring-based, and jet-based. By usability, the market is segmented into disposable and reusable needle free injectors.
By medication type, the needle free injection market is segmented into projectile/depot-based, powder-based, and liquid-based needle free injectors. By site of delivery, intradermal, intramuscular, and subcutaneous are segments in the market. Oncology, vaccination, insulin delivery, and others are major market applications. Prime end-users include ambulatory surgical centers, homecare settings, hospitals and clinics, and others.
The segments and sub-segments covered in the report are analyzed under four major regions –Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. For the scope of research, the standard definition of the product/ service “needle free injection” is included in the report. The report discusses and interprets the current and future opportunities of the industry delivering an unbiased growth assessment.
CROSSJECT, Medical International Technology, Inc., National Medical Products Inc., INJEX Pharma GmBH, PenJet Corporation, Valeritas Holdings, Inc., Antares Pharma Inc., D'Antonio Consultants International, Inc., MIKA MEDICAL CO., PharmaJet, Inc., Endo Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., and European Pharma Group are prominent players in the needle free injection market.
The report offers comprehensive profiles on these market players and assesses their current standing in the needle free injection market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, M&A activities, and latest R&D initiatives are outlined in the report.
Market Research Future (MRFR) uses a combination of primary and secondary research to compile market reports. Primary data is accumulated from interviewing industry stalwarts and secondary research is collated by studying white papers and annual reports of leading players. Our analysts use top-down and bottom-up approaches to validate the findings of the report. The report comprises news, current trends, and future prospects related to the market, all of which can provide a thorough understanding of the market to clients. Industry leaders can make accurate business decisions based on our insights.
The pharmaceutical business as we know it originated in Europe. It also houses the world's oldest and still functioning pharmaceutical firm, Merck KGaA, often known as the Merck Group in the United States, which marked its 350th anniversary in 2018. Europe and the United States continue to be the world's largest and most influential pharmaceutical markets. It's no surprise that the first widely authorized and used COVID-19 vaccine came from a joint venture between BioNTech in Germany and Pfizer in the United States.
Medical International Technology, Inc. is a company that manufactures, markets, and sells needle-free jet injector solutions for single and mass injections in people and animals. In the sphere of medical equipment, the company focuses on the medical and paramedical sectors The company's product lines include a home use injector for diabetics and other therapies that require daily injections, as well as a vaccine and other biological injectable medicines targeting physicians in their clinics.Report Overview
This report allows the user to gain a deeper understanding of the ongoing events and trends in the needle free injection market. By correlating the historical data with key market dynamics, our analysts were able to make highly accurate projections in the report. MRFR’s report includes a thorough segmental analysis of the global needle free injection market segmented by product type, test type, end-user, and region with astute insights. This report has been prepared to assist industry participants in making informed decisions on growth strategies and operation management. Users will also come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the needle free injection market during the assessment period.
For the scope of research, the report offers a comprehensive analysis of the global needle free injection market.
Type of Medication
Site of Delivery
|Market Size||USD 142.70 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product, Technology, Usability, Type of Medication, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||CROSSJECT, Medical International Technology, Inc., National Medical Products Inc., INJEX Pharma GmBH, PenJet Corporation, Valeritas Holdings, Inc., Antares Pharma Inc., D'Antonio Consultants International, Inc., MIKA MEDICAL CO., PharmaJet, Inc., Endo Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., and European Pharma Group|
|Key Market Opportunities||Prevalence of various chronic diseases|
|Key Market Drivers||Rise in investments in the pharmaceutical sector and convenient use of these medical devices in home care|
Needle free injections are syringes which deliver drugs through direct contact with the skin instead of a hypodermic needle. They can be used by children, adults, and patients with allergic conditions without any doctor supervision. It can prevent needle stick injuries, which is a common factor of disease transmission.
The needle free injection market expanding at an astounding CAGR of 17.50% during the forecast period (2022-2030).
The needle free injection market is anticipated to reach USD 142.70 Million by 2030, as per a new detailed report by Market Research Future (MRFR).
The key players of the global needle free injection market include MIKA MEDICAL CO., PharmaJet, Inc., PenJet Corporation, Inovio Pharmaceuticals Inc., D'Antonio Consultants International, Inc., National Medical Products Inc., Valeritas Holdings, Inc., CROSSJECT, INJEX Pharma GmBH, Endo Pharmaceuticals Inc., Antares Pharma Inc., Medical International Technology, Inc., and European Pharma Group.
Prevalence of various chronic diseases is propelling the need for needle free injections. Rise in investments in the pharmaceutical sector and convenient use of these medical devices in home care is projected to drive market growth over the forecast period.